Analysts forecast that Thermo Fisher Scientific Inc. (NYSE:TMO) will report $2.24 earnings per share for the current quarter, according to Zacks. Seven analysts have issued estimates for Thermo Fisher Scientific’s earnings. The highest EPS estimate is $2.28 and the lowest is $2.20. Thermo Fisher Scientific posted earnings per share of $2.03 in the same quarter last year, which suggests a positive year-over-year growth rate of 10.3%. The business is expected to issue its next quarterly earnings report on Thursday, October 26th.

On average, analysts expect that Thermo Fisher Scientific will report full year earnings of $9.24 per share for the current financial year, with EPS estimates ranging from $9.21 to $9.28. For the next year, analysts expect that the firm will post earnings of $10.24 per share, with EPS estimates ranging from $9.85 to $10.81. Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Thermo Fisher Scientific.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.27 by $0.03. The business had revenue of $5 billion for the quarter, compared to the consensus estimate of $4.92 billion. Thermo Fisher Scientific had a return on equity of 11.11% and a net margin of 12.27%. The business’s revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the business posted $2.03 EPS.

TMO has been the topic of several analyst reports. Cantor Fitzgerald initiated coverage on Thermo Fisher Scientific in a research note on Thursday, May 18th. They issued an “overweight” rating and a $194.00 price objective on the stock. Barclays PLC set a $175.00 price objective on Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Wednesday, April 26th. Cowen and Company reiterated an “outperform” rating and issued a $185.00 price objective (up from $175.00) on shares of Thermo Fisher Scientific in a research note on Saturday, April 29th. Citigroup Inc. reiterated a “buy” rating and issued a $201.00 price objective (up from $182.00) on shares of Thermo Fisher Scientific in a research note on Monday, July 10th. Finally, BidaskClub upgraded Thermo Fisher Scientific from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 11th. One equities research analyst has rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $188.56.

TRADEMARK VIOLATION WARNING: This report was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2017/08/22/thermo-fisher-scientific-inc-tmo-expected-to-post-earnings-of-2-24-per-share.html.

In related news, Director Jim P. Manzi sold 1,000 shares of the company’s stock in a transaction on Thursday, August 17th. The shares were sold at an average price of $175.20, for a total value of $175,200.00. Following the completion of the sale, the director now owns 38,757 shares in the company, valued at approximately $6,790,226.40. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Marc N. Casper sold 20,000 shares of the company’s stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $172.79, for a total transaction of $3,455,800.00. Following the completion of the sale, the chief executive officer now owns 269,279 shares of the company’s stock, valued at approximately $46,528,718.41. The disclosure for this sale can be found here. In the last 90 days, insiders sold 39,506 shares of company stock valued at $6,834,758. 0.49% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Thermo Fisher Scientific by 2.4% in the second quarter. Vanguard Group Inc. now owns 26,600,394 shares of the medical research company’s stock worth $4,640,970,000 after buying an additional 629,093 shares during the period. BlackRock Inc. boosted its position in Thermo Fisher Scientific by 1.6% in the second quarter. BlackRock Inc. now owns 23,355,469 shares of the medical research company’s stock worth $4,074,828,000 after buying an additional 366,584 shares during the period. Capital Research Global Investors boosted its position in Thermo Fisher Scientific by 29.8% in the second quarter. Capital Research Global Investors now owns 17,304,897 shares of the medical research company’s stock worth $3,019,185,000 after buying an additional 3,973,136 shares during the period. State Street Corp boosted its position in Thermo Fisher Scientific by 1.0% in the first quarter. State Street Corp now owns 16,085,954 shares of the medical research company’s stock worth $2,470,802,000 after buying an additional 164,367 shares during the period. Finally, Capital World Investors boosted its position in shares of Thermo Fisher Scientific by 6.1% in the second quarter. Capital World Investors now owns 11,759,734 shares of the medical research company’s stock valued at $2,051,721,000 after buying an additional 671,637 shares during the last quarter. Hedge funds and other institutional investors own 87.60% of the company’s stock.

Shares of Thermo Fisher Scientific (NYSE TMO) traded up 1.60% during mid-day trading on Tuesday, hitting $176.79. The company had a trading volume of 1,271,562 shares. The firm has a market cap of $68.97 billion, a PE ratio of 30.80 and a beta of 1.06. Thermo Fisher Scientific has a 12-month low of $139.07 and a 12-month high of $182.87. The firm’s 50 day moving average is $176.70 and its 200-day moving average is $166.92.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 15th will be given a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.34%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.45%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Get a free copy of the Zacks research report on Thermo Fisher Scientific (TMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc. and related stocks with our FREE daily email newsletter.